Related references
Note: Only part of the references are listed.Differences in drug approval processes of 3 regulatory agencies: a case study of gemtuzumab ozogamicin
Tetsuya Tanimoto et al.
INVESTIGATIONAL NEW DRUGS (2013)
Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia
Jason Kato et al.
LEUKEMIA RESEARCH (2013)
CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy
Joseph M. Tuscano et al.
CANCER RESEARCH (2012)
Antibody-drug conjugates - a perfect synergy
John R. Adair et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Epratuzumab-SN-38: A New Antibody-Drug Conjugate for the Therapy of Hematologic Malignancies
Robert M. Sharkey et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
Hagop Kantarjian et al.
LANCET ONCOLOGY (2012)
Targeting B lymphoma with nanoparticles bearing glycan ligands of CD22
Weihsu C. Chen et al.
LEUKEMIA & LYMPHOMA (2012)
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy
Hui Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma
Jason Kato et al.
ONCOIMMUNOLOGY (2012)
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
Ivana N. M. Micallef et al.
BLOOD (2011)
Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP
John F. DiJoseph et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
David J. FitzGerald et al.
CANCER RESEARCH (2011)
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart
CLINICAL CANCER RESEARCH (2011)
Investigational antibody-drug conjugates for hematological malignancies
Andrew G. Polson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells
Mary K. O'Reilly et al.
JOURNAL OF IMMUNOLOGY (2011)
Immunotoxins with decreased immunogenicity and improved activity
Ira Pastan et al.
LEUKEMIA & LYMPHOMA (2011)
In vivo targeting of B-cell lymphoma with glycan ligands of CD22
Weihsu C. Chen et al.
BLOOD (2010)
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne et al.
CLINICAL CANCER RESEARCH (2010)
Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non-Hodgkin's Lymphoma Xenograft Mouse Model
Joseph M. Tuscano et al.
CLINICAL CANCER RESEARCH (2010)
Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)
Robert T. O'Donnell et al.
INVESTIGATIONAL NEW DRUGS (2010)
Oversight of Fast-Track Drug Approval by FDA Stuck in Low Gear, Critics Say
Mike Mitka
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
High Rates of Durable Responses With Anti-CD22 Fractionated Radioimmunotherapy: Results of a Multicenter, Phase I/II Study in Non-Hodgkin's Lymphoma
Franck Morschhauser et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era
Grzegorz S. Nowakowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma
Matthew T. Drake et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
FDA Increases Focus on Postmarketing Studies
Merrill Goozner
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma
A. G. Polson et al.
LEUKEMIA (2010)
Efficacy and Toxicity of 2 Schedules of Frontline Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Plus Bortezomib in Patients With B-Cell Lymphoma
Vincent Ribrag et al.
CANCER (2009)
Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts
Robert T. O'Donnell et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Developmental Acquisition of the Lyn-CD22-SHP-1 Inhibitory Pathway Promotes B Cell Tolerance
Andrew J. Gross et al.
JOURNAL OF IMMUNOLOGY (2009)
Durable Complete Responses From Therapy With Combined Epratuzumab and Rituximab Final Results From an International Multicenter, Phase 2 Study in Recurrent, Indolent, Non-Hodgkin Lymphoma
John P. Leonard et al.
CANCER (2008)
Therapy of Advanced B-Lymphoma Xenografts with a Combination of 90Y-anti-CD22 IgG (Epratuzumab) and Unlabeled Anti-CD20 IgG (Veltuzumab)
M. Jules Mattes et al.
CLINICAL CANCER RESEARCH (2008)
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: A children's oncology group pilot study
Elizabeth A. Raetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Reinduction platform for children with first marrow relapse in acute lymphoblastic lymphoma
Elizabeth A. Raetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia
J. F. DiJoseph et al.
LEUKEMIA (2007)
Distinct endocytic mechanisms of CD22 (Siglec-2) and Siglec-F reflect roles in cell signaling and innate immunity
Hiroaki Tateno et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas
John M. Pagel et al.
CANCER RESEARCH (2007)
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An overview from the research on adverse drug events and reports (RADAR) project
June M. McKoy et al.
LEUKEMIA RESEARCH (2007)
Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab
Josette Carnahan et al.
MOLECULAR IMMUNOLOGY (2007)
Epratuzumab in the therapy of oncological and immunological diseases
David M. Goldenberg
EXPERT REVIEW OF ANTICANCER THERAPY (2006)
High-affinity ligand probes of CD22 overcome the threshold set by cis ligands for binding, endocytosis, and killing of B cells
Brian E. Collins et al.
JOURNAL OF IMMUNOLOGY (2006)
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
Sandra J. Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
B cell antigen receptor and CD40 differentially regulate CD22 tyrosine phosphorylation
M Fujimoto et al.
JOURNAL OF IMMUNOLOGY (2006)
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dose-fractionated radioimmunotherapy in non-Hodgkin's lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab
O Lindén et al.
CLINICAL CANCER RESEARCH (2005)
Follicular lymphoma international prognostic index
P Solal-Céligny et al.
BLOOD (2004)
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results
JP Leonard et al.
CLINICAL CANCER RESEARCH (2004)
Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production
RT Mott et al.
GLIA (2004)
CD22 regulates B lymphocyte function in vivo through both ligand-dependent and ligand-independent mechanisms
JC Poe et al.
NATURE IMMUNOLOGY (2004)
B cell defects in SLP65/BLNK-deficient mice can be partially corrected by the absence of CD22, an inhibitory coreceptor for BCR signaling
J Gerlach et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma
JP Leonard et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts
JM Tuscano et al.
BLOOD (2003)
Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)
JP Leonard et al.
SEMINARS IN ONCOLOGY (2002)
Difference in CD22 molecules in human B cells and basophils
K Toba et al.
EXPERIMENTAL HEMATOLOGY (2002)
CD22 regulates B cell receptor-mediated signals via two domains that independently recruit Grb2 and SHP-1
KL Otipoby et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
RJ Kreitman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
